SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-019433
Filing Date
2024-05-15
Accepted
2024-05-15 06:50:31
Documents
15
Period of Report
2024-05-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 38012
2 ex99-1.htm EX-99.1 45018
3 ex99-1_001.jpg GRAPHIC 6175
  Complete submission text file 0001493152-24-019433.txt   274315

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evfm-20240515.xsd EX-101.SCH 3009
5 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evfm-20240515_lab.xml EX-101.LAB 34916
6 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evfm-20240515_pre.xml EX-101.PRE 22785
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3752
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

IRS No.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36754 | Film No.: 24947065
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)